|
|
???tair.name??? >
???browser.page.title.author???
|
"okamoto i"???jsp.browse.items-by-author.description???
Showing items 1-5 of 5 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2020-05-26T09:26:51Z |
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials
|
Shah R; Märten A; Massey D; Wind S; Wu Y.-L.; Dickgreber N; Okamoto I; Sebastian M; Huang Y; Hirsh V; Lu S; O'Byrne K; Feng J; Wu Y.-L.;Wind S;Massey D;M?rten A;Shah R;Dickgreber N;Okamoto I;Sebastian M;Huang Y;Hirsh V;Lu S;O'Byrne K;Feng J;Yamamoto N;Hu C.-P;Mok T;Geater S.L;Schuler M;Zhou C;Sequist L.V;Chih-Hsin Yang; CHIH-HSIN YANG; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ?�real-world??clinical setting
|
Park K;Wan-Teck Lim D;Okamoto I;Chih-Hsin Yang; Park K; Wan-Teck Lim D; Okamoto I; CHIH-HSIN YANG |
| 臺大學術典藏 |
2019 |
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Nakagawa K.;Garon E.B.;Seto T.;Nishio M.;Ponce Aix S.;Paz-Ares L.;Chiu C.-H.;Park K.;Novello S.;Nadal E.;Imamura F.;Yoh K.;Jin-Yuan Shih;Au K.H.;Moro-Sibilot D.;Enatsu S.;Zimmermann A.;Frimodt-Moller B.;Visseren-Grul C.;Reck M.;Chu Q.;Cortot A.;Pujol J.-L.;Fabre E.;Lamour C.;Bischoff H.;Kollmeier J.;Kimmich M.;Engel-Riedel W.;Hammerschmidt S.;Sch?Tte W.;Syrigos K.;Ho J.C.M.;Au K.-H.;Ardizzoni A.;Pasello G.;Gregorc V.;Del Conte A.;Galetta D.;Takahashi T.;Kumagai T.;Hotta K.;Goto Y.;Hosomi Y.;Sakai H.;Takiguchi Y.;Kim Y.H.;Kurata T.;Yamaguchi H.;Daga H.;Okamoto I.;Satouchi M.;Ikeda S.;Kasahara K.;Atagi S.;Azuma K.;Aoe K.;Horio Y.;Yamamoto N.;Tanaka H.;Watanabe S.;Nogami N.;Ozaki T.;Koyama R.;Hirashima T.;Kaneda H.;Tomii K.;Fujita Y.;Seike M.;Nishimura N.;Kato T.;Ichiki M.;Saka H.;Hirano K.;Nakahara Y.;Sugawara S.;Kim S.-W.;Min Y.J.;Lee H.W.;Kang J.-H.;An H.J.;Lee K.H.;Kim J.-S.;Lee G.-W.;Lee S.Y.;Alexandru A.;Udrea A.A.;Juan-Vidal ?.;Nadal-Alforja E.;Gil-Bazo I.;Ponce-Aix S.;Rubio-Viqueira B.;Alonso Garcia M.;Felip Font E.;Fuentes Pradera J.;Coves Sarto J.;Lin M.-C.;Su W.-C.;Hsia T.-C.;Chang G.-C.;Wei Y.-F.;Su J.;Cicin I.;Goksel T.;Harputluoglu H.;Ozyilkan O.;Henning I.;Popat S.;Hatcher O.;Mileham K.;Acoba J.;Garon E.;Jung G.;Raj M.;Martin W.;Dakhil S.; Hirano K.; Nakahara Y.; Saka H.; Ichiki M.; Kato T.; Nishimura N.; Seike M.; Fujita Y.; Tomii K.; Kaneda H.; Hirashima T.; Koyama R.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Azuma K.; Atagi S.; Sch?tte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Wei Y.-F.; Chang G.-C.; Hsia T.-C.; Su W.-C.; Lin M.-C.; Coves Sarto J.; Fuentes Pradera J.; Felip Font E.; Alonso Garcia M.; Rubio-Viqueira B.; Ponce-Aix S.; Gil-Bazo I.; Nadal-Alforja E.; Juan-Vidal ?.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. |
| 國立成功大學 |
2019 |
Tissue and plasma EGFR mutation analysis in the FLAURA trial: Osimertinib versus Comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non–small cell lung cancer
|
Gray, J.E.;Okamoto, I.;Sriuranpong, V.;Vansteenkiste, J.;Imamura, F.;Lee, J.S.;Pang, Y.-K.;Cobo, M.;Kasahara, Kasahara K.;Cheng, Y.;Nogami, Nogami N.;Cho, E.K.;Su, W.C.;Zhang, G.;Huang, X.;Li-Sucholeiki, X.;Lentrichia, B.;Dearden, S.;Jenkins, S.;Saggese, M.;Rukazenkov, Y.;Ramalingam, S.S. |
| 國立臺灣大學 |
2015 |
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
|
Passaro, A.; Yang, J. C.; Ahn, M.; Dickgreber, N. J.; Halmos, B.; Hirsh, V.; Hochmair, M. J.; Levy, B. P.; de Marinis, F.; Mok, T.; O'Byrne, K.; Okamoto, I.; Schuler, M.; Sebastian, M.; Shah, R.; Tan, E.; Yamamoto, N.; Maerten, A.; Wind, S.; Carbone, D. P.; 楊志新 |
Showing items 1-5 of 5 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
